Danaher's Q3 2026 core revenue growth expectations reflect the company's July guidance of 2.0% to 3.0%, incorporating a roughly 250 basis point headwind from lower respiratory testing revenue at Cepheid compared with the prior year. Underlying trends in Life Sciences and Biotechnology segments, including mid-single-digit growth in bioprocessing orders, support potential for outcomes above guidance, while Diagnostics is projected flat. With earnings scheduled for October 21 and a new CEO in place, traders weigh the balance between segment momentum, acquisition integration effects from Masimo, and respiratory volatility when pricing the closely contested 1.5–3% and 3–4.5% ranges. Analyst revenue consensus around $6.95 billion implies modest year-over-year expansion consistent with these levels.